INTRODUCTION
Vestibular disorders are significant causes of balance dysfunction in humans. Loss of vestibular hair cells (HCs) has been described in a variety of vestibular disorders including Meniere's disease, 1 and those associated with aging, 2 aminoglycoside ototoxicity 3 and infections. Although the mammalian vestibular sensory epithelium is capable of spontaneously regenerating HCs after trauma, the extent of such regeneration is very limited. [4] [5] [6] [7] [8] Currently, treatment of vestibular dysfunction largely focuses on central compensation, which does not treat the causative vestibular HC loss. Moreover, many patients fail to benefit from currently available treatments. Hearing aids or cochlear implants may be used as alternatives in the deaf; however, no artificial device has yet been developed to assist patients with vestibular functional loss. Therefore, vestibular HC protection or regeneration remains important in preventing or alleviating vestibular dysfunction.
Gene therapy, a promising molecular approach toward triggering vestibular HC regeneration, [9] [10] [11] offers hope to patients who need restoration of adequate vestibular function. Successful transfection of excised human vestibular epithelia has yielded proof of the principle that viral gene transfer might restore cellular function in patients suffering from vestibular disorders. 12 Although improvements in hearing and vestibular function have been achieved via gene transfer in several experimental models, 10, 11, 13, 14 inner ear gene therapy still remains at the experimental level. Improvements in both viral vectors and delivery routes are essential if the safe and practical application of gene transfer techniques in the inner ear is to be implemented clinically.
Adenovirus gene vectors are frequently used for vestibular gene therapy. Using such vectors, the regeneration or protection of vestibular HCs has been successfully achieved in several animal models. For example, Atoh1 overexpression by an adenovirus vector promotes vestibular HC regeneration and recovery of balance functionality in ototoxin-treated adult murine vestibules. [9] [10] [11] In addition, glial-cell-line-derived neurotrophic factor or Bcl-2 expressed from adenoviral vectors has been shown to prevent vestibular HC degeneration induced by aminoglycoside. 15, 16 However, because adenoviral vectors typically do not become integrated into host genome, therapeutic genes carried by these vectors are expressed only transiently. The host immune response to the adenoviral vectors is also a concern. 17 In contrast, adeno-associated virus (AAV) affords efficient transfer and long-term expression of therapeutic genes in a variety of post-mitotic tissues, with minimal vector-related pathogenicity. 18 Such advantages render the use of AAV vectors attractive when long-term effects are required, such as phenotypic rescue in the case of mutations or providing protection and maintenance. 14 Several AAV serotypes have been tested for gene transfer in various tissues. Because different AAV serotypes exhibit different transduction specificities among cell types, 18, 19 AAV serotypes that efficiently infect cells in the vestibular sensory epithelium should be used when the protection or regeneration of vestibular HCs is required. Kilpatrick et al. 20 examines AAV-mediated gene delivery into the scala media of adult mouse ear and reports that AAV8 has satisfactory tropism for vestibular sensory epithelium. However, the scala media inoculation method requires elaborate and challenging surgical steps, and also causes cochlear injury.
In humans, it is imperative to preserve hearing and balance functions during and after viral inoculations. In contrast, canalostomy offers a minimally invasive and highly efficient transfection route for inner ear gene therapy; there is no HC loss, and hearing and vestibular functions are not compromised. 22, 23 Furthermore, semicircular canal occlusion is safe and highly effective in patients with benign paroxysmal positional vertigo and superior canal dehiscence, 24 suggesting that canalostomy would be clinically feasible. In the current study, we examined whether AAV8 could efficiently transfect vestibular HCs and supporting cells (SCs) via the canalostomy route.
The traumatized vestibular sensory epithelium undergoes scar formation and cell transdifferentiation, 6, 7 which in turn could affect the number or type of cells infected by AAV. However, AAV-mediated gene transfer in the traumatized vestibular epithelium still needs to be illuminated. In addition, studies on the temporal bone in humans have shown that SCs survive many diseases associated with vestibular dysfunction. 1, 3 Therefore, a promising approach is the design of a therapeutic process triggering transdifferentiation of surviving SCs into HCs in patients with vestibular disorders. It is essential to define an effective vector that allows efficient transduction of SCs in the damaged vestibule.
In the present study, we examined the transduction efficiency of AAV serotypes (AAV1, AAV2, AAV5, AAV6 and AAV8) in the normal mouse utricle using canalostomy inoculation to identify an AAV serotype exhibiting favorable tropism toward the vestibular sensory epithelium. We found that AAV8 was the most efficient vector in terms of vestibular gene transfer. We also measured the time course of gene overexpression after AAV8 inoculation via canalostomy into normal mouse utricles by dynamic calculation of transduction efficiencies of AAV8 for vestibular HCs and SCs to define an optimal time window for local inoculation of AAV8 expressing genes of interest. Furthermore, we determined the extent of AAV8-mediated gene delivery in streptomycin-damaged mouse utricles to develop future gene-based therapies, which allow HC regeneration in injured mammalian vestibular endorgans.
RESULTS
AAV serotype-mediated transduction in mouse utricle Five AAV serotypes (AAV1, AAV2, AAV5, AAV6 and AAV8) were used to transduce normal adult mice. No apparent manifestations of vestibular dysfunction were observed 24 h after inoculation. Six animals showed significant lymphatic fluid leakage at the injection site and were excluded from the study. The canalostomy procedure is illustrated in Figure 1a , the study flowchart is shown in Figure 1b , and the number of utricles analyzed for each group is shown in Table 1 .
The transduction characteristics of each AAV serotype were assessed 30 days after surgery using immunofluorescence staining. In the AAV8 group (Figures 2a-aʹʹ) , robust green fluorescent protein (GFP) expression, reflecting high numbers of transduced cells, was noted throughout the sensory epithelium of the utricle (Figure 2a ). Immunostaining for myosin VIIa, a marker of HCs, revealed that HC numbers were approximately normal (Figure 2aʹ ). In the AAV2 group (Figures 2b-bʹʹ) , the number of GFP-positive cells was clearly lower than in the AAV8 group. In the AAV6 group (Figures 2c-cʹʹ) , sparse GFP expression was observed, principally in the transitional epithelium and the marginal regions of the sensory epithelium. In the AAV1 and AAV5 groups, GFP expression was rarely detected (data not shown).
Because GFP expression in utricles was sparse after transduction with AAV1, AAV5 or AAV6, we only calculated the transduction efficiencies of AAV2 and AAV8 in utricles 30 days after the addition of 1 μl virus suspension. The HC transduction efficiency of AAV8 was significantly higher than that of AAV2 (40.61 ± 6.83% vs 7.17 ± 5.07%, P o 0.05). Similar results were observed when the SC transduction efficiency was evaluated (57.06 ± 6.85% vs 9.29 ± 4.74%, P o 0.05). Thus, GFP transduction was optimal when AAV8 was used; use of AAV2 afforded some expression; and AAV6, AAV1 and AAV5 did not afford satisfactory expression. Therefore, AAV8 was selected for all subsequent experiments. Abbreviation: AAV, adeno-associated virus.
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Functional evaluation and gene overexpression in normal mouse utricle using AAV8 Seven normal mice were subjected to swim test 25 at 3, 7 and 30 days after the injection of 1 μl AAV8 suspension. Two (2/7) mice exhibited irregular swimming patterns 3 days after surgery (swim score, 1); however, they returned to normal 7 and 30 days post canalostomy (swim score, 0). The remaining mice (5/7) exhibited no abnormality in the swim test. Eight control mice that received normal saline injections were also subjected to swim test. Two (2/8) mice swam irregularly 3 days after surgery (swim score, 1), which became normal 7 and 30 days post canalostomy. The remaining mice (6/8) exhibited no abnormality in the swim test. Three (3/3) positive control mice received streptomycin and exhibited underwater tumbling (swim score, 3) 3, 7 and 30 days after canalostomy. Videos of swim test were shown as Supplementary Data.
Auditory brainstem response (ABR) measurements were performed in eight normal mice preoperatively and 7 days after injection of 1 μl AAV8 via canalostomy. The ABR thresholds 7 days after AAV8 injection did not differ from the preoperative results at 4, 8, 16 and 32 kHz (P40.05, Figure 3 ).
Immunofluorescence staining revealed abundant GFP-positive cells 3 days after AAV8 infection ( Figure 4a ) with no noticeable loss of HC, based on staining for myosin VIIa (Figure 4aʹ ). Extensive GFP expression was found in utricles 7 days postoperatively ( Figure 4b ). We next determined the spatial distribution of GFP using high-magnification microscopy. At the level of the cuticular plate, numerous GFP+/myosin VIIa+ cells (transduced HCs) were AAV8 transduction in the traumatized utricle As reported previously, 7 severe HC loss in the mouse utricle was evident 7 days after local application of streptomycin. Subsequently, AAV8 inoculation was performed via the posterior semicircular canal to explore transduction characteristics in injured utricles. As shown in Figure 5a , GFP distributed throughout such utricles by 7 days following AAV8 infusion. Discrete HCs, either surviving or regenerated, were located principally in the regions of the striola and lateral extrastriola (Figure 5aʹ ). In addition, GFP immunofluorescence was brighter in regions devoid of HCs than areas with HCs ( Figure 5aʹʹ) . Compared with the 7-day data, no noticeable difference was evident in samples obtained 30 days after AAV8 infusion, except that more HCs were apparent, particularly in the region of the middle extrastriola (Figures 5b-bʹʹ) .
High-magnification images revealed that the HC layer at the level of the cuticular plate exhibited intense GFP expression (Figures 6a-a‴) . Most GFP-positive cells were negative for myosin VIIa, suggesting that the cells were transduced SCs. HCs with immature hair bundles were also detected ( Figures  6aʹ and aʹʹ) , and the merged image demonstrated that AAV8 had effectively transduced the HCs (Figure 6a‴ ). At the nuclear layer of the SCs, numerous cells were positive for GFP (Figures 6b-bʹʹ and c) .
In traumatized utricles obtained 3 days after AAV8 transduction, five of eight had small numbers of GFP-positive cells. In contrast, extensive GFP expression was detected throughout the utricles of the other three samples (data not shown). Because of this variation, data on this group were excluded in the following quantitative analysis of transduction efficiency.
Quantitative analysis of transduction efficiency after AAV8 infusion First, to determine the time course of gene overexpression in normal utricles using AAV8, we calculated dynamic transduction efficiencies after AAV8 infusion. The HC transduction efficiency at 7 days (38.28 ± 4.12%) was significantly higher than that at 3 days (21.62 ± 5.47%), and the efficiency was stable to 30 days (40.61 ± 6.83%). However, no statistically significant difference in SC transduction efficiency was evident between the three time points (3 days (62.57 ± 9.10%), 7 days (63.85 ± 6.16%) and 30 days (57.06 ± 6.85%)), indicating that SC transduction efficiency peaked as early as 3 days after transfection.
Second, to explore whether an increased injected volume of AAV8 might elevate transduction efficiency, we measured transduction efficiencies 30 days after infusion of 2-μl amounts of AAV8 suspension. Neither HC transduction efficiency (45.13 ± 10.33%) nor SC transduction efficiency (49.11 ± 7.87%) differed significantly from those observed when 1-μl amounts of AAV8 suspension were applied.
Finally, in traumatized utricles, we restricted the quantification of the transduction efficiency to SCs, because most HCs were lost and a limited number of regenerated HCs were likely to be present. In addition, the 3-day group was excluded from analysis because of the extreme variability noted. In traumatized utricles, the SC transduction efficiency decreased from 7 to 30 days (69.59 ± 13.94% vs 46.09 ± 6.35%, P o 0.05). Also, the number of GFP-positive SCs decreased significantly from 7 to 30 days (1412 ± 290 vs 819 ± 73, P o 0.05). This was also true of the total number of SCs (2031 ± 112 vs 1786 ± 88, P o 0.05). No statistically significant difference in SC transduction efficiencies between normal and traumatized utricles was evident at the same time point after virus infusion ( Figure 7 ). 
DISCUSSION

AAV for vestibular gene therapy
The present study examined several AAV serotypes, including AAV1, AAV2, AAV5, AAV6 and AAV8. The results indicated that AAV8 was the most effective vector for gene delivery to the mouse utricle, although the AAV8 titer was considerably lower than that of any other AAV vector tested. These data are consistent with previous reports of high transduction efficiency using AAV8 in other tissues, including the cochlea, liver, heart and skeletal muscle. 20, [26] [27] [28] Immunostaining in the current study failed to identify any morphological abnormality in utricular sensory epithelium after AAV8 transduction, suggesting that AAV8 is safe for vestibular gene transfer.
It has been found that AAV1 transfects both vestibular HCs and SCs efficiently when delivered either via canalostomy 23 or in utero. 29 However, AAV infection is common in humans, and neutralizing antibodies against AAV1, AAV2 and AAV3 are found in a significant proportion of subjects. 30, 31 As such, the efficacy of AAV gene therapy using these immunogenic viral serotypes might be compromised in patients expressing AAV-neutralizing antibodies. In contrast, AAV8 is a primate virus (isolated from rhesus monkeys), and unlikely to be recognized and inactivated by human antibodies. 32, 33 The minimal immunogenicity of AAV8 increases its potential utility for gene therapy applications in humans.
Our data showed that both vestibular HCs and SCs were transduced efficiently by AAV8 containing a cytomegalovirus promoter. Alternative promoters have been used to drive the celltype-specific expression of target genes within the cochlea, such as the Myo7a promoter for gene expression in HCs, and the glial fibrillary acidic protein promoter for gene expression in SCs. 11, [34] [35] [36] Therefore, high-efficiency HC-specific gene transfer in the vestibular system might be possible using AAV8 with the Myo7a promoter, whereas AAV8 with the glial fibrillary acidic protein promoter might be appropriate for SC-specific gene transfer.
Canalostomy approach for vestibular gene transfer Kilpatrick et al. 20 reported that AAV8 efficiently transduced SCs and type II HCs in the mouse utricle using the scala media inoculation method. In the current study, we employed canalostomy, a more accessible and clinically feasible delivery route. This less-invasive approach yielded a comparable transduction rate to that reported by Kilpatrick et al. 20 Although a small number of mice in both AAV8 and saline injection groups swam mildly irregularly 3 days after surgery, swimming was normal at 7 and 30 days postoperatively. In addition, no pathological change was evident in the utricular sensory epithelium after AAV transduction via canalostomy. These data suggest that the temporary impairment of vestibular function caused by canalostomy is very mild. The ABR results in the current study revealed that the method of 1.0-μl inoculated volume by canalostomy preserved hearing (Figure 3 ). These findings are consistent with previous studies showing that the approach of canalostomy causes no HC loss and minimum impairment of hearing and vestibular function. 16, 22, 23 In addition, the lateral and posterior semicircular canals can be easily accessed in human subjects without exposing the middle ear cavity. Therefore, canalostomy is a satisfactory approach for vestibular gene therapy and shows promise in terms of future clinical applications.
Optimum virus inoculation volume and gene overexpression in the normal utricle using AAV8 To determine the ideal AAV level for vestibular gene transfer, the transduction efficiencies after infusion of 1-μl or 2-μl amounts of AAV8 suspension were evaluated. We found no difference in the transduction efficiencies of either HCs or SCs, suggesting that 1-μl amounts of the virus suspension at the current titer we used were sufficient for optimal cell transfection in the mouse utricle.
To define the optimal time window for the local inoculation of AAV8 vectors containing useful genes, the time course of gene overexpression after AAV8 inoculation was measured in whole mounts of utricles by dynamically calculating the transduction efficiencies of vestibular HCs and SCs. These issues have not been addressed in the study by Kilpatrick et al. 20 or other studies. Our results revealed that the transduction of HCs and SCs in the normal utricle using AAV8 peaked at different time points. Peak effects of 7 days after transfection in HCs indicated that AAV8 vectors expressing exogenous genes should be applied at least 7 days prior to the insult to protect HCs. In SCs of the normal utricle, an exogenous gene may become stably expressed as early as 3 days after AAV8 transfer.
Currently, it remains unclear why GFP was expressed as early as 3 days, particularly in SCs. Because vector-cell transduction depends largely on the expression of the viral receptors and co-receptors required for cell entry, 37 we speculate that it might Asterisks indicate significant differences between groups (P < 0.05). T-1μl-7d and T-1μl-30d signify 7 and 30 days after infusion of 1 μl AAV8 vector suspension into traumatized utricles, respectively.
be associated with the possible presence of AAV8 receptors in the vestibular sensory epithelium, particularly in SCs. However, the expression of AAV8 receptors in the mouse utricle has not yet been demonstrated. Another reason is likely to be use of the GFP antibody for detection. Without staining for GFP, far fewer GFP-positive cells with only weak fluorescence were detected in utricles 3 days after AAV transduction (data not shown). Nevertheless, the cause of this expression is yet to be elucidated.
Gene transfer by AAV8 in the traumatized utricle Another key difference between the current study and that by Kilpatrick et al. 20 is that gene transfer was performed to both the normal and traumatized vestibular epithelium in the current work, compared with only the normal vestibular epithelium in the study by Kilpatrick et al. 20 because the application of kanamycin and furosemide has little impact on the vestibular HCs and SCs. It is important to understand the transduction characteristics of the vector in lesioned utricles for the therapeutic treatment of HC loss. In this study, after establishing a streptomycin-induced lesion, most HCs were lost and the apical surfaces of SCs expanded ( Figure 6 ). The SCs were thus directly exposed to viral particles. However, quantitative analysis of SC transduction efficiency revealed no significant difference between normal and traumatized utricles at the same time points after viral infusion (Figure 7b) . Indeed, the GFP fluorescence intensity of SCs in lesioned utricles appeared to be stronger than that of SCs in normal utricles (data not shown). The question of whether more GFP is overexpressed in lesioned compared with normal utricles requires further quantitative analysis.
Some variation was evident in the transduction efficiencies of traumatized mouse utricles 3 days after AAV8 injection, which may be attributable to scar formation and spontaneous HC transdifferentiation. 7 The SC transduction efficiency peaked 7 days after AAV8 transduction, suggesting that 7 days must elapse after AAV8-mediated delivery before an exogenous gene is sufficiently overexpressed in SCs to allow for HC regeneration.
A slight decline in SC transduction efficiency was observed in traumatized mouse utricles 30 days after AAV8 infusion ( Figure 7b) ; the numbers of both GFP-positive SCs and all SCs were reduced (Figures 7c and d) . This could be attributable to conversion of some transfected SCs to HCs in the interval from 7 to 30 days. 38 Transduced HCs with immature hair bundles were found in traumatized utricles (Figures 6a-a‴) ; these are suggested to be new HCs transdifferentiated from transduced SCs.
Limitation and future directions
The limitation of the current study was the lack of comprehensive functional outcomes and use of therapeutic genes. Nevertheless, our study revealed that AAV8 was the most effective serotype for gene transfer targeting the vestibular system in adult mice, and identified the optimal time window for vector delivery. These findings pave the way for carrying out additional functional studies, such as protecting vestibular HCs or enhancing HC regeneration, using AAV8 vectors expressing specific target genes in the future.
CONCLUSIONS
We characterized utricular transgene expression from several AAV serotypes injected into normal and traumatized mouse inner ears using the canalostomy route. We demonstrated that, among these serotypes, AAV8 was the most effective for gene transfer into the sensory epithelium of the mouse utricle, and was also associated with minimal damage to vestibular function and hearing. In the normal utricle, transduction efficiency after AAV8 infusion peaked at 7 days for HCs and 3 days for SCs. Transduction was stable over time. In the lesioned utricle, SC transduction efficiency peaked at 7 days and fell slightly by 30 days after AAV8 transfer. AAV8 infusion via canalostomy efficiently transduced the vestibular sensory epithelia of both normal and traumatized mouse utricles, with few side effects.
MATERIALS AND METHODS
AAV vectors
Purified AAV-GFP vectors of serotypes 1, 2, 5 and 6 were purchased from Vector Biolabs (Philadelphia, PA, USA), with titers of 1 × 10 13 vg ml − 1 . Purified AAV8-GFP vector was purchased from Vector Gene Technology Company Limited (Beijing, China), and had a titer of 5 × 10 11 vg ml − 1
. AAV vectors of all five tested serotypes were generated by tripartite transfection into HEK293 cells. GFP expression in these vectors was driven by the cytomegalovirus promoter. For AAV-GFP vectors of serotypes 1, 2, 5 and 6, a pAAV-GFP cis-plasmid, an Ad helper plasmid and an AAV Rep/Cap plasmid were used, and viral particles were purified using serial CsCl centrifugations. For the AAV8-GFP vector, a pSNAV2.0-GFP plasmid, an Ad helper plasmid and an AAV Rep2/Cap8 plasmid were used, and AAV8-GFP particles were purified using ion-exchange column chromatography. All viruses were stored in phosphate-buffered saline (PBS) at -80°C.
Animals and surgery
All animal experiments were conducted according to the guidelines of the Animal Care and Use Committee of the Capital Medical University of China. Five to six week-old-female CD-1 mice (Vital River Laboratory Animal Technology, Beijing, China) were anesthetized with intraperitoneal injection of xylazine (7 mg kg − 1 ; Sigma, St Louis, MO, USA) and ketamine HCl (120mg kg − 1 ; Gutian Pharmaceutical Co., Gutian, China). Ketoprofen (10mg kg − 1 ; Sigma) was given subcutaneously immediately prior to each operation. The surgery was performed only on the left side of the ear. The skin surrounding the incision was shaved and sterilized with 75% (v/v) alcohol. A postauricular incision was made and the muscles were separated to expose the posterior or lateral semicircular canal (Figure 1a) .
To test AAV-mediated transfection characteristics in normal utricles, 1 or 2 μl AAV vector suspensions was inoculated into the posterior semicircular canal at a rate of 0.5 μl min − 1 . Surgery was performed as described previously. 6, 7 In traumatized mice, 2 μl streptomycin in normal saline (75 μl min − 1 ; Sigma) were administered into the lateral semicircular canal; this caused almost complete loss of utricle HCs. The surgical procedures were carried out as described previously, 6, 7 except that inoculation was performed via the lateral semicircular canal. Traumatized mice were allowed to recover for 7 days prior to virus inoculation through the posterior semicircular canal. Control mice received an equivalent volume of normal saline. Mice were killed 3, 7 and 30 days after AAV infusion.
Evaluation of vestibular function and ABR measurements
Vestibular functional evaluation was performed as described previously. 25 Manifestations of vestibular dysfunction (circling, head-tilting, abnormal gait and longitudinal body-axis rotation) were recorded. For the swim test, a container with water at least 15-cm-deep, at 24-26°C, was prepared, and each mouse was lowered carefully into the water by gripping the animal by the tail. Swimming ability was assessed and swimming scores 25 were recorded. Each mouse was then placed on a heated mat in a cage to ensure warming after the swim test. Normal mice without virus or saline injections and mice that had received streptomycin injections served as negative and positive controls, respectively.
ABR measurements of the virus-injected ear (left side) were recorded preoperatively and 7 days after the AAV8 inoculation. After anesthetization, animals were placed in an audiometric chamber (Shanghai Shengnuo Acoustic Equipment Company Limited, Shanghai, China). Needle electrodes were inserted beneath the pinna of the test ear (−) and at the vertex (+), with a ground electrode in the contralateral ear. The acoustic stimuli were generated using Tucker-Davis Technologies equipment (Tucker-Davis Technologies, Alachua, FL, USA). ABRs were evoked at octave frequencies of 4-32 kHz with 5-ms duration tone bursts. A total of 1024 responses were averaged near the threshold at various intensities with 5-dB intervals. The lowest level at which ABR waves could be clearly detected was defined as the threshold. Statistical analyses were performed using Student's t-tests (Prism 5, GraphPad Software, Inc., La Jolla, CA, USA) for the ABR data, and differences were considered to be significant when P ⩽0.05.
Immunofluorescence staining Animals were decapitated under deep anesthesia. Temporal bones were fixed in 4% paraformaldehyde in PBS overnight at 4°C. After rinsing in PBS three times for 5 min each, the utricles were dissected out and the otolith membranes were removed. Tissues were then treated with 0.3% (v/v) Triton X-100 (Sigma) in PBS for 30 min, and blocked in 10% (v/v) normal goat serum in PBS for 60 min at room temperature. The tissues were next incubated with rabbit anti-GFP (diluted 1:400; Invitrogen/Molecular Probes, Carlsbad, CA, USA) and mouse anti-myosin VIIa (diluted 1:300; Hybridoma Bank, Iowa, IA, USA) primary antibodies overnight at 4°C. After rinsing in PBS three times for 5 min each, samples were incubated with secondary antibodies labeled with Alexa Fluor 488, 568 or 647 (diluted 1:300; Invitrogen/Molecular Probes) for 1 h at room temperature. Samples were incubated in Alexa Fluor 594-conjugated phalloidin (diluted 1:300; Invitrogen/Molecular Probes) for 1 h if actin labeling was required. The DNA-binding fluorescent stain 4′,6-diamidino-2-phenylindole (DAPI; diluted 1:500; AppliChem, St Louis, MO, USA) was used in some experiments to label nuclei for 5 min. After staining, specimens were mounted on glass slides with the aid of Fluoromount-G (SouthernBiotech, Birmingham, AL, USA).
Next, confocal images were obtained using a Leica scanning confocal microscope (Leica Camera AG, Solms, Hessen, Germany) with 20 × and 63 × objective lenses for low-magnification and high-magnification analysis, respectively. A 63 × objective lens with a 2 × digital zoom was used to capture HC images through the plane of the cuticular plate, and SC images through the plane of the SC nuclei. Pictures were cropped, labeled and spaced using the Adobe Photoshop software.
Cell counts and data analysis
Cell counts were performed on confocal images of utricles stained with DAPI and antibodies against GFP and myosin VIIa, using the tpsDig software (Version 2.16, F James Rohlf, Ecology & Evolution, SUNY at Stony Brook, Stony Brook, NY, USA). Using a 63 × objective lens with a 2 × digital zoom, six non-overlapping views (~90 μm × 90 μm per view) were randomly captured from both the HC and SC layers of each utricle. In the HC layer, GFP-positive/myosin VIIa-positive cells (transduced HCs) and myosin VIIa-positive cells (HCs) were counted. In the SC layer, GFP-positive cells (transduced SCs) and DAPI-positive cells (SCs) were counted. Subsequently, cell counts from each of the six views were summed. For each sample, the proportion of transduced HCs among all HCs was calculated to yield HC transduction efficiency, and the SC transduction efficiency was similarly derived. Three-to-five utricles were analyzed for each group. Data were averaged over the utricles in each group, and the statistical significance of differences was determined by Analysis of Variance (Prism 5). Differences were considered statistically significant if the P-value was ⩽ 0.05 after sequential Bonferroni adjustment for multiple testing.
